Literature DB >> 2479986

Vascular endothelial growth factor is a secreted angiogenic mitogen.

D W Leung1, G Cachianes, W J Kuang, D V Goeddel, N Ferrara.   

Abstract

Vascular endothelial growth factor (VEGF) was purified from media conditioned by bovine pituitary folliculostellate cells (FC). VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis in vivo. Complementary DNA clones for bovine and human VEGF were isolated from cDNA libraries prepared from FC and HL60 leukemia cells, respectively. These cDNAs encode hydrophilic proteins with sequences related to those of the A and B chains of platelet-derived growth factor. DNA sequencing suggests the existence of several molecular species of VEGF. VEGFs are secreted proteins, in contrast to other endothelial cell mitogens such as acidic or basic fibroblast growth factors and platelet-derived endothelial cell growth factor. Human 293 cells transfected with an expression vector containing a bovine or human VEGF cDNA insert secrete an endothelial cell mitogen that behaves like native VEGF.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479986     DOI: 10.1126/science.2479986

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  1100 in total

1.  Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch.

Authors:  M Félétou; J Staczek; J Duhault
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment.

Authors:  A J Hayes; L Y Li; M E Lippman
Journal:  BMJ       Date:  1999-03-27

3.  Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor.

Authors:  Rizwan Masood; Ethel Cesarman; D Lynne Smith; Parkash S Gill; Ornella Flore
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 5.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 6.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

7.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

8.  Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

Authors:  S Yi; M S Tsao
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

9.  Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4.

Authors:  Hairong Peng; Vonda Wright; Arvydas Usas; Brian Gearhart; Hsain-Chung Shen; James Cummins; Johnny Huard
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

10.  A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  John K Chan; Wei Deng; Robert V Higgins; Krishnansu S Tewari; Albert J Bonebrake; Michael Hicks; Stephanie Gaillard; Pedro T Ramirez; Weldon Chafe; Bradley J Monk; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2017-07-18       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.